Lipid Controls
Avanti Polar Lipids 1,2-dihexanoyl-sn-glycero-3-phosphocholine, 34506-67-7, MFCD00050431, 25 mg
Molecular Formula: C20H40NO8P, Formula Weight: 453.507, Purity >99%.
Avanti Polar Lipids 330820 ULTIMATESPLASH ONE
330820 UltimateSPLASH ONEUltimateSPLASH ONE Internal Standard for Lipidomic Analysis
Medchemexpress LLC Glyco-diosgenin | 1402423-29-3 | >=97% | 1165.31 g/mol | 5 MG
Glyco-diosgenin (GDN) is a synthetic drop-in substitute for Digitonin. It is intended for research use only and not for use in human, therapeutic, or diagnostic applications. All products should be handled by qualified personnel trained in laboratory procedures.
- Purity (HPLC): ≥97%
- Supplied as a powder
Sigma Aldrich Fine Chemicals Biosciences 1-Stearoyl-sn-glycero-3-phosphocholine | 19420-57-6 | MFCD00050427 | 5mg
1-Stearoyl-sn-glycero-3-phosphocholine | Purity: ≥99% | Mol Wt: 523.68 | 19420-57-6 | MFCD00050427 | 5mg
Cayman Chemical Lyso-PAF C-18 1mg
Lyso-PAF C-18 can be formed by either the action of PAF-AH on PAF C-18{2626} or by the action of a CoA-independent transacylase on 1-O-octadecyl-2-acyl-glycerophosphocholine.{240,2098} Lyso PAF C-18 is a substrate for eitherPAF C-18 formation by the remodeling pathway{939} or selective acylation with arachidonic acid by a CoA-independent transacylase.{2101}
Avanti Polar Lipids Hexadecyl Coenzyme A (ammonium salt), 71425-89-3, 5 mg
Molecular Formula: C37H77N10O16P3S, Formula Weight: 1042.445, Purity >99%.
Cayman Chemical 1 3DIoleoyl2Decnoyl Glyce 10mg
A triacylglycerol; has been found in transitional human milk
Avanti Polar Lipids 18:1 CDP DG 5MG
18:1 CDP DG >99% 5mg Powder 1,2-dioleoyl-sn-glycero-3-(cytidine diphosphate) (ammonium salt) CAS#799812-77-4 C48H91N5O15P2
Avanti Polar Lipids Cardiolipin (Heart, Bovine) (sodium salt) Chloroform | 383907-10-6 | 50mg
Cardiolipin (Heart, Bovine) (sodium salt) Chloroform | Purity: 99% | 383907-10-6 | 50mg
Cayman Chemical 1 3DIoleoyl2Decnoyl Glyce 25mg
A triacylglycerol; has been found in transitional human milk
Cayman Chemical DLIn-KC2-DMA 10mg
An ionizable cationic lipid (pKa = 6.7); has been used in the formation of LNPs encapsulating siRNA or plasmid DNA for use in vitro and in vivo; LNPs containing DLin-KC2-DMA selectively accumulate in the liver after i.v. or i.m. administration in mice or localize to the retinal pigment epithelium and Müller glia after subretinal administration; DLin-KC2-DMA-containing LNPs encapsulating F7-targeted siRNA reduce serum Factor VII levels in mice; DLin-KC2-DMA-containing LNPs encapsulating AR-targeted siRNA decrease serum PSA and tumor androgen receptor levels in an LNCaP prostate cancer mouse xenograft model
Avanti Polar Lipids 18:1 (Δ9-Cis) PE (DOPE), 4004-05-1, MFCD16621009, powder, 500mg
Molecular Formula C41H78NO8P, Purity >99%, Formula Weight 744.034, Storage Temperature -20°C, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine